Game-changer HIV shot approved in US may enter Canada by 2026; Just two injections a year
Agencies
Canada reviews groundbreaking twice-a-year HIV prevention shot after US approval, offering hope but raising concerns over access and cost
A twice-a-year injectable drug being hailed as a breakthrough in HIV prevention could be available in Canada as early as mid-2026, offering new hope in the fight against the virus.
The drug, lenacapavir, developed by Gilead Sciences, was approved by the US Food and Drug Administration (FDA) last week for pre-exposure prophylaxis (PrEP). It is the first and only HIV prevention medication that requires just two doses per year. Gilead Canada submitted the drug to Health Canada in April for review, which was accepted earlier this month.
Lenacapavir was approved in Canada in 2022 for treatment, but this is the first time it's under review for prevention.'This is absolutely a monumental advance in prevention,' said Peter Newman, a professor at the University of Toronto whose work focuses on HIV prevention. 'It's certainly cost-effective in the long run because you're going to prevent a lot of cases of new HIV.'
Lenacapavir works by creating a slow-release 'depot' of medicine under the skin, delivering protection for six months. Clinical trials showed near-total effectiveness: among more than 2,000 high-risk women in Africa, zero new infections were recorded. In another trial among gay and bisexual men and transgender women, only two infections occurred, both in participants who were already HIV-positive before the injection.
Gilead's US list price is $28,218 a year, sparking concerns about access and affordability, especially for marginalized groups. 'We could get a lot of interest, but if people can't afford it, it's dead in the water,' O'Byrne said.Currently in Canada, 54 percent of PrEP prescriptions are paid for by private insurance and 43 percent by public programs, according to the Public Health Agency of Canada. Gilead says it will work with both public and private payers to 'accelerate availability and access.'If approved, the shot will only be available through healthcare providers, doctors, or nurses. But experts argue it should be expanded to include pharmacists and nurse practitioners, especially to increase access in remote or underserved areas.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Economic Times
7 hours ago
- Economic Times
Game-changer HIV shot approved in US may enter Canada by 2026; Just two injections a year
Agencies Canada reviews groundbreaking twice-a-year HIV prevention shot after US approval, offering hope but raising concerns over access and cost A twice-a-year injectable drug being hailed as a breakthrough in HIV prevention could be available in Canada as early as mid-2026, offering new hope in the fight against the virus. The drug, lenacapavir, developed by Gilead Sciences, was approved by the US Food and Drug Administration (FDA) last week for pre-exposure prophylaxis (PrEP). It is the first and only HIV prevention medication that requires just two doses per year. Gilead Canada submitted the drug to Health Canada in April for review, which was accepted earlier this month. Lenacapavir was approved in Canada in 2022 for treatment, but this is the first time it's under review for prevention.'This is absolutely a monumental advance in prevention,' said Peter Newman, a professor at the University of Toronto whose work focuses on HIV prevention. 'It's certainly cost-effective in the long run because you're going to prevent a lot of cases of new HIV.' Lenacapavir works by creating a slow-release 'depot' of medicine under the skin, delivering protection for six months. Clinical trials showed near-total effectiveness: among more than 2,000 high-risk women in Africa, zero new infections were recorded. In another trial among gay and bisexual men and transgender women, only two infections occurred, both in participants who were already HIV-positive before the injection. Gilead's US list price is $28,218 a year, sparking concerns about access and affordability, especially for marginalized groups. 'We could get a lot of interest, but if people can't afford it, it's dead in the water,' O'Byrne in Canada, 54 percent of PrEP prescriptions are paid for by private insurance and 43 percent by public programs, according to the Public Health Agency of Canada. Gilead says it will work with both public and private payers to 'accelerate availability and access.'If approved, the shot will only be available through healthcare providers, doctors, or nurses. But experts argue it should be expanded to include pharmacists and nurse practitioners, especially to increase access in remote or underserved areas.
Time of India
9 hours ago
- Time of India
Game-changer HIV shot approved in US may enter Canada by 2026; Just two injections a year
A twice-a-year injectable drug being hailed as a breakthrough in HIV prevention could be available in Canada as early as mid-2026, offering new hope in the fight against the virus. The drug, lenacapavir , developed by Gilead Sciences , was approved by the US Food and Drug Administration (FDA) last week for pre-exposure prophylaxis (PrEP). It is the first and only HIV prevention medication that requires just two doses per year. Gilead Canada submitted the drug to Health Canada in April for review, which was accepted earlier this month. Lenacapavir was approved in Canada in 2022 for treatment, but this is the first time it's under review for prevention. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Free P2,000 GCash eGift UnionBank Credit Card Apply Now Undo 'This is absolutely a monumental advance in prevention,' said Peter Newman, a professor at the University of Toronto whose work focuses on HIV prevention. 'It's certainly cost-effective in the long run because you're going to prevent a lot of cases of new HIV.' How does it work Live Events Lenacapavir works by creating a slow-release 'depot' of medicine under the skin, delivering protection for six months. Clinical trials showed near-total effectiveness: among more than 2,000 high-risk women in Africa, zero new infections were recorded. In another trial among gay and bisexual men and transgender women, only two infections occurred, both in participants who were already HIV-positive before the injection. Very expensive Gilead's US list price is $28,218 a year, sparking concerns about access and affordability, especially for marginalized groups. 'We could get a lot of interest, but if people can't afford it, it's dead in the water,' O'Byrne said. Currently in Canada, 54 percent of PrEP prescriptions are paid for by private insurance and 43 percent by public programs, according to the Public Health Agency of Canada. Gilead says it will work with both public and private payers to 'accelerate availability and access.' If approved, the shot will only be available through healthcare providers, doctors, or nurses. But experts argue it should be expanded to include pharmacists and nurse practitioners, especially to increase access in remote or underserved areas.
Time of India
16 hours ago
- Time of India
State-wide survey for TB from today, ASHA workers enlisted
1 2 Jaipur: With the deadline for eliminating tuberculosis (TB) in the state approaching in Dec this year, health department will start a major state-wide survey to identify patients and vulnerable people from Wednesday. The department has enlisted accredited social health activists (ASHA), who will be paid Rs 10 per family surveyed. According to estimates, Jaipur has the highest number of vulnerable population at 15.9 lakh, followed by Jodhpur (8.8 lakh), Alwar (8.7 lakh), Nagaur (7.8 lakh), and Udaipur (7.3 lakh). The state has a fleet of over 50,000 ASHA workers. They will conduct a door-to-door survey to identify vulnerable people, such as those with HIV or diabetes, those above 60 years of age, smokers, alcoholics, undernourished, tribal groups, migrants, and miners. A health department official said their teams will survey high-risk settings, such as brick kilns, construction sites, mining areas, jails, hostels, congregate settings, and slum areas to find active cases of TB. The survey will end on July 11. You Can Also Check: Jaipur AQI | Weather in Jaipur | Bank Holidays in Jaipur | Public Holidays in Jaipur During the door-to-door survey, if a person shows symptoms of TB, health department teams will conduct confirmatory TB tests such as sputum tests, X-rays, and other diagnostic tests. If the person is diagnosed with TB, they will be put on treatment, and health workers in the area will conduct follow-ups to ensure they are taking timely treatment.
